The first two oral antivirals, molnupiravir and nirmatrelvir–ritonavir, are now becoming
available in many countries. These medicines will be indicated to treat mild-to-moderate …

First reports of cases and case series of COVID-19-associated pulmonary aspergillosis
(CAPA) emerged during the first months of the pandemic. Prevalence rates varied widely …

The role of hypoxia, vascular endothelial injury, and thrombotic inflammation in worsening
COVID-19 symptoms has been generally recognized. Damaged vascular endothelium plays …

Outcome of early treatment of COVID‐19 with antivirals or anti‐spike monoclonal antibodies
(MABs) in patients with haematological malignancies (HM) is unknown. A retrospective …

Background Little is known on the burden of co-infections and superinfections in a specific
setting such as the respiratory COVID-19 sub-intensive care unit. This study aims to (i) …

Drug treatment of COVID-19 infection : Current Opinion in Pulmonary Medicine Drug treatment
of COVID-19 infection : Current Opinion in Pulmonary Medicine Log in or Register Subscribe to …

Background COVID-19 disease is accompanied by a dysregulated immune response and
hypercoagulability. The Anti-Coronavirus Therapies (ACT) inpatient trial aimed to evaluate …

Purpose Although there is evidence supporting the benefits of corticosteroids in patients
affected with severe coronavirus disease 2019 (COVID-19), there is little information related …

Remdesivir (Veklury®), a nucleotide analogue prodrug with broad-spectrum antiviral activity,
is approved for the treatment of coronavirus disease 2019 (COVID-19), the illness caused by …

Background Community-acquired pneumonia (CAP) is associated with high morbidity and
mortality. In the present study, we aimed to assess the effect of corticosteroids on all-cause …